Late treatment study
et al., J. Zhejiang University (Med Sci), doi:10.3785/j.issn.1008-9292.2020.03.03 (Peer Reviewed)
A pilot study of hydroxych loroquine in treatment of patients with common coronavirus disease-19 (COVID-19)
30 moderate hospitalized cases, all recovered. Time to RNA negative comparable. Less frequent radiological progression with HC
Q but not statistically significant. One HC
Q patient developed to a severe case. Treatment group 4 years older and with higher incidence of hypertension.
disease progression, ↓29.0%, p=0.57, risk of radiological progression
no virological cure, ↑100%, p=1.00, risk of viral+ at day 7
Please send us corrections, updates, or comments.